During the course of the past 40 years, we have launched and developed five highly-respected journals, which largely fund our charitable activities. This includes our grants programme, biennial congress, and the European Academy of Microbiology (EAM).
The EAM is a leadership group of around 150 eminent microbiology experts who came together in 2009 to amplify the impact of microbiology and microbiologists in Europe.
|Year||EAM’s Key initiatives|
|2011||Article – the enemy within us: lessons from the 2011 European Escherichia coli O104:H4 outbreak|
|2011||Workshop – participation at the FEMS Congress 2011 included a 2 hour EAM/EMF-led Keynote Lecture and Roundtable Discussion on “Emerging Diseases — Pandemics, Drug Resistance and Vaccines”|
|2012||Seminar – a seminar addressing Coinfections was hosted by the European Academy of Microbiology (EAM) and the German National Academy of Sciences in Leopoldina. Ten speakers presented. A Special Edition ‘Co-infections’ was produced by the EAM and EMF in FEMS Journal Pathogens and Disease. It included a total of 10 x mini reviews / research articles.|
|2013||Workshop – Infection Diagnostics and Infection Biology|
|2014||Workshop – a retreat workshop with a number of presentations|
|2015||Special event – at FEMS 2015, EAM chaired the special event ‘Microbiome and human health’|
|2016||Workshop – a retreat workshop with a number of presentations|
|2017||Workshop – at FEMS2017, EAM chaired a workshop ‘Bacterial Survival Strategies’|
|2018||Workshop – a retreat workshop with a number of presentations
The aim of this study was to determine whether in vitro induced erythromycin resistance facilitates the cross-resistance to the novel fluoroketolide, solithromycin, in Staphylococcus aureus. Long-term exposure of erythromycin results in resistance to ketolides in S. aureus through drug binding site mutations. These results demonstrate that since erythromycin has been used clinically for a long time, it is necessary to carefully evaluate the rewards and risks when prescribing solithromycin for the treatment of infectious diseases.